<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496000</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-007</org_study_id>
    <nct_id>NCT02496000</nct_id>
  </id_info>
  <brief_title>Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Diet and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, parallel group study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel group
      study. After appropriate screening, approximately 180 male and female patients from up to 33
      study centers will be treated in this study. Patients with type 2 diabetes mellitus who are
      being treated by diet, exercise, untreated with antidiabetic medications or treated with and
      metformin monotherapy or in combination with one other antidiabetic drug (excluding insulin)
      are eligible for enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.</measure>
    <time_frame>Baseline-Study day -7 (± 1 day) through Study day 1 (± 1 day), and Week 4 -Study day 22 (± 1 day) through Study day 29 (± 1 day)</time_frame>
    <description>The Effect of ORMD-0801 (Doses 1 &amp; 2, Pooled) on Mean Night Time Glucose Levels (measured in mg/dL) Based on 2 Nights of Continuous Glucose Monitor (CGM) Data by Comparison of the Mean Change Between Baseline and Wk 4 of ORMD-0801 Treatment and Placebo Groups. The primary analysis will be based on the results from the two last days, unless technical difficulties preclude calculation of the weighted mean glucose levels. In this case, the last two days (selected between days 5, 6, and 7) with at least 80% of the expected number of measurements will be used. If days 5, 6 and 7 do not have 2 days with at least 80% of the expected number of measurements for a specific subject, then the value will be missing for that subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Mean 24-hour Glucose</measure>
    <time_frame>Study day -7 (± 1 day) through Study day 1 (± 1 day), and Study day 22 (±1 day) - Study day 29 (± 1 day)</time_frame>
    <description>The effect of ORMD-0801 (Dose 1 and Dose 2 individually and pooled) on mean 24-hour glucose based on 2 nights of CGM data by comparison of the mean change between baseline and Wk 4 of ORMD-0801 treatment and the placebo groups measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Difference of Mean (mg/dL) Fasting Glucose From Baseline to Week 4</measure>
    <time_frame>Study day 1 (± 1 day) through Study day 29 (± 1 day)</time_frame>
    <description>The effect of ORMD-0801 (Dose 1 and Dose 2 pooled and individually) on absolute changes from baseline to Wk 4 in fasting morning blood glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ORMD-0801 on Mean Daytime Glucose</measure>
    <time_frame>Study day 1 (±1 day) through Study day 29 (± 1 day)</time_frame>
    <description>The effect of ORMD-0801 (Dose 1 and Dose 2 pooled and individually) on changes from baseline to Wk 4 of Continuous Glucose Monitoring (CGM) of mean daytime glucose, measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Changes in HbA1c</measure>
    <time_frame>Study day 1 (± 1 day) through Study day 29 (± 1 day)</time_frame>
    <description>The effect of ORMD-0801 (Dose 1 and Dose 2 pooled and individually) on percent changes from baseline to Wk 4 in HbA1c</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>three identical capsules containing placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose 2 = 1.5 * Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801</intervention_name>
    <description>Oral Insulin</description>
    <arm_group_label>ORMD-0801 Dose 1</arm_group_label>
    <arm_group_label>ORMD-0801 Dose 2 = 1.5 * Dose 1</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c ≥7.5% if naïve to antidiabetic therapy; ≥6.5% and ≤10% if on metformin ≥1,500 mg
             daily; ≥6.5% and ≤9.5% if on monotherapy with an antidiabetic drug other than
             metformin; ≥ 6.5% and ≤9.5% if on metformin and one other antidiabetic drug; ≥ 7.0% if
             on metformin &lt;1,500 mg daily.

          -  At time of randomization, patients will be treated for their diabetes by diet,
             exercise, and metformin (≥1500 mg/day; any type and regimen). Patients will have been
             on a stable regimen of metformin (defined as the same metformin dose and type) for at
             least two weeks prior to entering the single-blind placebo run-in period.

          -  Other antidiabetic agents will not be used for the two weeks prior to entering the
             placebo run-in period.

          -  Patients in whom the maximum tolerated dose (MTD) of metformin is 1,000 mg will be
             allowed to enter the study.

          -  At Day -7 (Visit 3), all patients will have HbA1c ≥ 6.5% and ≤10%.

          -  Body Mass Index between 25 and 40 kg/m2, inclusive.

          -  Fasting blood glucose ≥ 126 mg/dL (8.3 mmol/L) prior to randomization at Day -7 (Visit
             3). For patients in whom the Day -7 (Visit 3) fasting blood glucose is &lt;126 mg/dL and
             ≥ 115 mg/dL, and the Day -7 (Visit 3) HbA1C is ≥ 7% and ≤ 10%, a minimum of 5 daily
             self- monitored fasting blood glucose checks recorded in the patient diary can be
             averaged. If the average value is ≥ 126 mg/dL, the patient may continue in the trial.

          -  Females of childbearing potential must have a negative urine pregnancy test result at
             screening. A negative urine pregnancy test must be obtained during Visit 2 and at
             Visit 4 (prior to randomization).

          -  Males and females of childbearing potential must use two methods of contraception
             (double barrier method), one of which must be an acceptable barrier method from the
             time of screening to the last study visit (Day 43).

          -  Patient has &gt;80% compliance with placebo during run in prior to randomization.

          -  Patient has ≥ 80% of the glucose readings on at least two 24 hour periods (6AM - 6AM)
             during the seven day CGM period.

          -  Patient has performed ≥ 10/14 of the self monitored glucose level measurements during
             placebo run-in, prior to randomization.

        Exclusion Criteria:

        - Patients who meet any of the following criteria are not eligible for this study.

          -  Presence of any clinically significant endocrine disease according to the Investigator
             (euthyroid patients on replacement therapy will be included if the dosage of thyroxine
             is stable for at least six weeks prior to Screening Visit).

          -  Clinical diagnosis of Type 1 diabetes.

          -  Fasting blood glucose &gt;260 mg/dL at the end of Day -7/Visit 3. For patient in whom the
             Day 07 (Visit 3) fasting blood glucose is &gt; 260 mg/dL and &lt; 300 mg/dL, and the Day -7
             (Visit 3) HbA1C is ≥ 7% and ≤ 10%, a minimum of 5 self-monitored fasting blood glucose
             checks recorded in the patient diary can be averaged. If the average value is ≤ 260
             mg/dL, the patient may continue in the trial.

          -  Presence or history of cancer within the past five years with the exception of
             adequately-treated localized basal cell skin cancer or in situ uterine cervical
             cancer.

          -  Laboratory abnormalities at screening including:

               1. C-peptide &lt; 1.0 ng/mL.

               2. Positive pregnancy test in females of childbearing potential (at screening and
                  start of run-in period).

               3. Abnormal serum thyrotropin (TSH) levels &gt;1.5 times the upper limit of normal.

               4. Positive test for hepatitis B surface antigen and/or hepatitis C antibody.

               5. Positive test for HIV.

               6. Serum Cr &gt;1.4mg/dl in males, &gt;1.3mg/dl in females.

               7. Any relevant abnormality interfering with the efficacy or the safety assessments
                  during study drug administration.

          -  Use of the following medications:

               1. History of use of insulin for greater than one week in the last six months and
                  any use of insulin in the last six weeks prior to randomization.

               2. Administration of anti-diabetic drugs other than metformin within four weeks
                  prior to randomization visit. Administration of thyroid preparations or thyroxine
                  within six weeks prior to screening visit. (Patients on stable thyroid
                  replacement therapy for greater than 6 weeks may enter the study.)

          -  Administration of systemic long-acting corticosteroids within two months or prolonged
             use (more than one week) of other systemic corticosteroids or inhaled corticosteroids
             within 30 days prior to screening visit.

          -  Use of medications known to modify glucose metabolism or to decrease the ability to
             recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed
             above), beta blockers (with the exception of beta blocker ophthalmic solutions for
             glaucoma or ocular hypertension), and immunosuppressive or immunomodulating agents.

          -  History of tobacco or nicotine use in excess of two packs/day within ten weeks prior
             to screening.

          -  Patient is on a weight loss program and is not in the maintenance phase, or patient
             that started any approved or non approved weight loss medication within eight weeks
             prior to screening.

          -  Pregnancy or breast-feeding.

          -  Patient has a screening visit systolic blood pressure of ≥160 mm Hg or diastolic blood
             pressure of ≥100 mm Hg Patients will be allowed to take BP medication as long as they
             have been on a stable dose for a period of four weeks prior to the screening visit.

          -  Patient is, at the time of signing informed consent, a user of recreational or illicit
             drugs or has had a recent history (within the last year) of drug or alcohol abuse or
             dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by &gt;3 drinks
             per day or &gt;14 drinks per week, or binge drinking).

          -  Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST),
             alkaline phosphatase) greater than two times the upper limit of normal at screening.

          -  Very high triglyceride level (&gt;500 mg/dL) at screening.

          -  Any clinically significant electrocardiogram (ECG) abnormality at screening or
             cardiovascular disease. Clinically significant cardiovascular disease will include:

               1. History of stroke, transient ischemic attack, or myocardial infarction within six
                  months prior to screening,

               2. History of or currently have New York Heart Associate Class II-IV heart failure
                  prior to screening, or

               3. Uncontrolled hypertension defined as blood pressure ≥160 mmHg (systolic) or ≥100
                  mmHg (diastolic) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Neutel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steingard Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Primary Care Clinic, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dream Team Clinical Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACTCA, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACTCA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills-Peninsula Health Services</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creekside Endocrine Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research in Miami Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research in Miami, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ormond Medical Arts Pharmaceutical Research Center</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute, Inc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Medical Research, MI, Inc</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Padre Coast Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panacea Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>December 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2017</results_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus type 2</keyword>
  <keyword>Metformin</keyword>
  <keyword>oral insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study design: screening, followed by a 14 day wash-out followed by a 14-day single-blind run-in prior to the 28-day treatment period. Efficacy based on the Intend-to-treat population 80% trimming of the data. The safety (adverse events) data is based on the safety population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Comparator</title>
          <description>three identical capsules containing placebo
Placebo Comparator: Placebo</description>
        </group>
        <group group_id="P2">
          <title>ORMD-0801 Dose 1</title>
          <description>three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
ORMD-0801: Oral Insulin</description>
        </group>
        <group group_id="P3">
          <title>ORMD-0801 Dose 2 = 1.5 * Dose 1</title>
          <description>three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
ORMD-0801: Oral Insulin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance or lack of cooperation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>undetermined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Comparator</title>
          <description>three identical capsules containing placebo
Placebo Comparator: Placebo</description>
        </group>
        <group group_id="B2">
          <title>ORMD-0801 Dose 1</title>
          <description>three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
ORMD-0801: Oral Insulin</description>
        </group>
        <group group_id="B3">
          <title>ORMD-0801 Dose 2 = 1.5 * Dose 1</title>
          <description>three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
ORMD-0801: Oral Insulin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.61" spread="9.203"/>
                    <measurement group_id="B2" value="57.89" spread="8.021"/>
                    <measurement group_id="B3" value="57.25" spread="8.786"/>
                    <measurement group_id="B4" value="57.92" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.</title>
        <description>The Effect of ORMD-0801 (Doses 1 &amp; 2, Pooled) on Mean Night Time Glucose Levels (measured in mg/dL) Based on 2 Nights of Continuous Glucose Monitor (CGM) Data by Comparison of the Mean Change Between Baseline and Wk 4 of ORMD-0801 Treatment and Placebo Groups. The primary analysis will be based on the results from the two last days, unless technical difficulties preclude calculation of the weighted mean glucose levels. In this case, the last two days (selected between days 5, 6, and 7) with at least 80% of the expected number of measurements will be used. If days 5, 6 and 7 do not have 2 days with at least 80% of the expected number of measurements for a specific subject, then the value will be missing for that subject.</description>
        <time_frame>Baseline-Study day -7 (± 1 day) through Study day 1 (± 1 day), and Week 4 -Study day 22 (± 1 day) through Study day 29 (± 1 day)</time_frame>
        <population>Intend-to-Treat Population, 80% trimming. The mean values will be analyzed using a one-way analysis of variance (ANOVA) model. The residuals from the ANOVA will be analyzed to verify that they are normally distributed. If not normally distributed, then a Kruskal-Wallis test (one-way analysis of variance on the ranks) will be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator</title>
            <description>three identical capsules containing placebo
Placebo Comparator: Placebo</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose 1</title>
            <description>three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
ORMD-0801: Oral Insulin</description>
          </group>
          <group group_id="O3">
            <title>ORMD-0801 Dose 2 = 1.5 * Dose 1</title>
            <description>three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
ORMD-0801: Oral Insulin</description>
          </group>
          <group group_id="O4">
            <title>ORMD-0801 Doses 1 and 2 Combined</title>
            <description>The combined measurements of dose 1 and dose 2, in units of mg/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.</title>
          <description>The Effect of ORMD-0801 (Doses 1 &amp; 2, Pooled) on Mean Night Time Glucose Levels (measured in mg/dL) Based on 2 Nights of Continuous Glucose Monitor (CGM) Data by Comparison of the Mean Change Between Baseline and Wk 4 of ORMD-0801 Treatment and Placebo Groups. The primary analysis will be based on the results from the two last days, unless technical difficulties preclude calculation of the weighted mean glucose levels. In this case, the last two days (selected between days 5, 6, and 7) with at least 80% of the expected number of measurements will be used. If days 5, 6 and 7 do not have 2 days with at least 80% of the expected number of measurements for a specific subject, then the value will be missing for that subject.</description>
          <population>Intend-to-Treat Population, 80% trimming. The mean values will be analyzed using a one-way analysis of variance (ANOVA) model. The residuals from the ANOVA will be analyzed to verify that they are normally distributed. If not normally distributed, then a Kruskal-Wallis test (one-way analysis of variance on the ranks) will be performed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.70" spread="26.140"/>
                    <measurement group_id="O2" value="-3.67" spread="18.983"/>
                    <measurement group_id="O3" value="6.64" spread="26.361"/>
                    <measurement group_id="O4" value="1.66" spread="23.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This outcome measure requires that the the mean differences of ORMD-0801 in each of the two arms be pooled.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>ANOVA model on the ranks</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Mean 24-hour Glucose</title>
        <description>The effect of ORMD-0801 (Dose 1 and Dose 2 individually and pooled) on mean 24-hour glucose based on 2 nights of CGM data by comparison of the mean change between baseline and Wk 4 of ORMD-0801 treatment and the placebo groups measured in mg/dL</description>
        <time_frame>Study day -7 (± 1 day) through Study day 1 (± 1 day), and Study day 22 (±1 day) - Study day 29 (± 1 day)</time_frame>
        <posting_date>03/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference of Mean (mg/dL) Fasting Glucose From Baseline to Week 4</title>
        <description>The effect of ORMD-0801 (Dose 1 and Dose 2 pooled and individually) on absolute changes from baseline to Wk 4 in fasting morning blood glucose.</description>
        <time_frame>Study day 1 (± 1 day) through Study day 29 (± 1 day)</time_frame>
        <posting_date>03/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of ORMD-0801 on Mean Daytime Glucose</title>
        <description>The effect of ORMD-0801 (Dose 1 and Dose 2 pooled and individually) on changes from baseline to Wk 4 of Continuous Glucose Monitoring (CGM) of mean daytime glucose, measured in mg/dL</description>
        <time_frame>Study day 1 (±1 day) through Study day 29 (± 1 day)</time_frame>
        <posting_date>03/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Changes in HbA1c</title>
        <description>The effect of ORMD-0801 (Dose 1 and Dose 2 pooled and individually) on percent changes from baseline to Wk 4 in HbA1c</description>
        <time_frame>Study day 1 (± 1 day) through Study day 29 (± 1 day)</time_frame>
        <posting_date>03/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>eight (8) months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Comparator</title>
          <description>three identical capsules containing placebo
Placebo Comparator: Placebo</description>
        </group>
        <group group_id="E2">
          <title>ORMD-0801 Dose 1</title>
          <description>three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
ORMD-0801: Oral Insulin</description>
        </group>
        <group group_id="E3">
          <title>ORMD-0801 Dose 2 = 1.5 * Dose 1</title>
          <description>three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
ORMD-0801: Oral Insulin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Non-Treatment Emergent Adverse Event</sub_title>
                <description>Basal Ganglia Stroke</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joel M. Neutel, M. D.</name_or_title>
      <organization>Orange County Research Center</organization>
      <phone>714-541-5591</phone>
      <email>jmneutel@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

